Jiangsu Province Nanjing Brain Hospital clinical trials
Jiangsu Province Nanjing Brain Hospital is the lead sponsor of 9 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Paliperidone Palmitate. The most-studied condition is Adolescent.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Jiangsu Province Nanjing Brain Hospital
9 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
HD-tDCS for Adolescent Bipolar Depression Targeting S1
NCT07246044 · ClinicalTrials.gov ↗ · Adolescent, Bipolar Depression, tDCS
|
Not applicable | Recruiting | 2025-10 | China |
|
Effect of Music Therapy in Mental Subhealth (EMTMS)
NCT05648539 · ClinicalTrials.gov ↗ · Depression, Anxiety
|
Not applicable | Recruiting | 2023-04 | China |
|
40 Hz Flickering for Insomnia in Parkinson's Disease
NCT07323121 · ClinicalTrials.gov ↗ · Parkinson Disease, Insomnia
|
Not applicable | Recruiting | 2026-01 | China |
|
Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease
NCT07299240 · ClinicalTrials.gov ↗ · Parkinson Disease (PD), Insomnia
|
Not applicable | Recruiting | 2026-01 | China |
|
Multimodal Phenotyping in Adolescent Inpatient Depression: An Observational Study
NCT07247344 · ClinicalTrials.gov ↗ · Adolescent, Major Depressive Disorder (MDD, Bipolar Disorder (BD)
|
Observational | Recruiting | 2025-03 | China |
|
The Effects of Low-Intensity Music in Adolescents With Anxiety
NCT07492472 · ClinicalTrials.gov ↗ · Anxiety
|
Not applicable | Recruiting | 2025-12 | China |
|
Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
NCT07075237 · ClinicalTrials.gov ↗ · Schizophrenia
Drug: Paliperidone Palmitate |
Phase 4 | Not yet open | 2025-10 | China |
|
TIS for Brain Network Modulation and Clinical Efficacy in Parkinson's Disease
NCT07480317 · ClinicalTrials.gov ↗ · PARKINSON DISEASE (Disorder)
|
Not applicable | Not yet open | 2026-03 | China |
|
Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease
NCT07317557 · ClinicalTrials.gov ↗ · Cerebral Small Vessel Disease, Cognitive Impairment
|
Not applicable | Not yet open | 2026-04 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Jiangsu Province Nanjing Brain Hospital trials
1 compoundDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Jiangsu Province Nanjing Brain Hospital trials
15 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 6 |
A trial with sites in more than one country appears in each of those registers.
Questions about Jiangsu Province Nanjing Brain Hospital trials
How many clinical trials does Jiangsu Province Nanjing Brain Hospital sponsor?
Jiangsu Province Nanjing Brain Hospital is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.
Are Jiangsu Province Nanjing Brain Hospital trials recruiting?
Yes. 6 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Jiangsu Province Nanjing Brain Hospital testing?
Its current trials name 1 drug or biological as interventions. The most frequent are Paliperidone Palmitate (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.